Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alkermes (ALKS)
NASDAQ:ALKS
Holding ALKS?
Track your performance easily
ALKS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$22.90 - $32.88
Previous Close$29.71
Volume4.64M
Average Volume (3M)1.75M
Market Cap
$4.81B
Enterprise Value$4.26B
Total Cash (Recent Filing)$908.86M
Total Debt (Recent Filing)$366.00M
Price to Earnings (P/E)15.1
Beta0.74
Next Earnings
Feb 13, 2025EPS Estimate
$0.75Last Dividend Ex-Date
Nov 16, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)1.96
Shares Outstanding161,802,508
10 Day Avg. Volume1,950,105
30 Day Avg. Volume1,749,653
Standard Deviation0.10
R-Squared0.05
Alpha0.00539
Financial Highlights & Ratios
Price to Book (P/B)3.72
Price to Sales (P/S)3.19
Price to Cash Flow (P/CF)14.70
P/FCF Ratio16.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.83
Enterprise Value/Gross Profit3.02
Enterprise Value/Ebitda8.35
Forecast
1Y Price Target
$36.36Price Target Upside22.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Alkermes News
PremiumCompany Announcements
Alkermes Prepares for New Flexibility Post Credit Termination
PremiumCompany Announcements
Alkermes Aims for Growth with Neuroscience Focus
Bulls Say, Bears Say
Bulls Say
Analyst ConfidenceAnalyst reiterates an Outperform rating and raises the price target from $35 to $40, indicating confidence in the stock's performance.
Market PotentialManagement believes the market potential for narcolepsy is large, with narcolepsy type I alone potentially being a multi-billion opportunity for the orexin-2 receptor agonist class.
Product EfficacyALKS-2680 is the only orexin-2 receptor agonist to demonstrate efficacy in narcolepsy type I, narcolepsy type II, and idiopathic hypersomnia conditions in a Phase 1b trial.
Bears Say
Financial PerformanceOverall manufacturing & royalty revenues of $105.1M were below consensus.
Product Safety ConcernsThere is concern about the safety risks, including liver toxicity and visual disturbances, although these are somewhat mitigated by low dosing and analogs.
Research And DevelopmentManagement expects EBITDA to decrease in 2025, with an expected negative impact in royalty and manufacturing revenue.
---
Ownership Overview
1.49% Insiders
35.24% Mutual Funds
23.87% Other Institutional Investors
4.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALKS FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was $22.90 and its highest was $32.88 in the past 12 months.
What is Alkermes’s market cap?
Currently, no data Available
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is Feb 13, 2025 which is in 53 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on Oct 24, 2024. The company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.7 by $0.02.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes pays a Notavailable dividend of $1.639 which represents an annual dividend yield of N/A. See more information on Alkermes dividends here
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is $0.75.
How many shares outstanding does Alkermes have?
Alkermes has 161,802,500 shares outstanding.
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of $0.72 in its last earnings report, beating expectations of $0.7. Following the earnings report the stock price went down -3.591%.
Which hedge fund is a major shareholder of Alkermes?
Among the largest hedge funds holding Alkermes’s share is Baker Bros Advisors LP. It holds Alkermes’s shares valued at 117M.
---
Alkermes Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.36 (22.38% Upside)
$36.36 (22.38% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 262.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.30%
12-Months-Change
Fundamentals
Return on Equity
29.23%
Trailing 12-Months
Asset Growth
-5.44%
Trailing 12-Months
Company Description
Alkermes
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
---
ALKS Company Deck
---
ALKS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented strong growth metrics in the proprietary product portfolio, especially VIVITROL and LYBALVI, and a solid financial position. However, there are challenges in the schizophrenia market and expected declines in royalty and manufacturing revenues, impacting future profitability.Read More>---
ALKS Revenue Breakdown
55.31% Product sales, net
44.69% Manufacturing and royalty revenues
<0.01% Research and development revenue
0.00% License revenue
---
ALKS Stock 12 Month Forecast
Average Price Target
$36.36
▲(22.38% Upside)
Technical Analysis
Best Analysts Covering ALKS
1 Year
1 Year Success Rate
16/20 ratings generated profit
1 Year Average Return
+8.15%
reiterated a buy rating 2 days ago
Copying Uy Ear's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +8.15% per trade.
---